Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07816146

China Elderly Valve Disease Study III (China-DVD3 Study)

This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart disease. To systematically evaluate the distribution of types, clinical characteristics, interventions, and complications of elderly valvular heart disease, and to compare and analyze these with the China-DVD data from 2016, thereby revealing its evolutionary trends. By comprehensively considering various clinical characteristics such as different types of valvular lesions, treatment modalities, patient cardiac function, comorbidities, and blood test indicators, as well as multidimensional factors including psychological and lifestyle aspects, to deeply identify the key determinants influencing the treatment of elderly valvular heart disease patients in China, and thus optimize and improve their individualized comprehensive management pathways.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fuwai Hospital, National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100037, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hospitalized patients over 60 years old meet one of the following conditions.

1、 moderate or above valvular heart disease as defined by echocardiography: One of the following criteria

  • (1)Mitral stenosis : Valve area ≤1.5 cm², or mean pressure gradient ≥10 mmHg.
  • (2)Mitral regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant jet area/left atrial area > 20%; or effective regurgitant orifice area (EROA) ≥ 20 mm²
  • (3)Aortic stenosis : Moderate and above, mean pressure gradient ≥ 20 mmHg, or peak jet velocity ≥ 3 m/s, or valve area ≤ 1.5 cm²
  • (4)Aortic regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant fraction ≥ 30%, or jet width occupying ≥ 25% of the left ventricular outflow tract, or effective regurgitant orifice area (EROA) ≥ 10 mm²
  • (5)Tricuspid stenosis : Moderate and above
  • (6)Tricuspid regurgitation : Moderate and above regurgitation, or jet area ≥ 5 cm²
  • (7)Pulmonary stenosis : Moderate and above
  • (8)Pulmonary regurgitation : Moderate and above regurgitation 2 、Previous history of cardiac valve surgery or interventional therapy (dilation, valvuloplasty, valve replacement) 3、Diagnosed with infective endocarditis

Exclusion criteria

Patients unwilling to accept registration and follow-up;

  • Patients with mental illness who cannot cooperate with information collection and follow-up Patients have been enrolled in this study.

Treatment and study plan

Primary outcomes

  1. First valve intervention during this hospitalization

    Time frame: From enrollment to the end of treatment at 12 weeks

    Underwent their first internal medicine intervention or surgical procedure during hospitalization for valvular heart disease in this study

Secondary outcomes

  1. 1、Repeat valve intervention 2、Cardiovascular adverse events

    Time frame: From enrollment to the 12-month follow-up endpoint

    1 、Repeat valve intervention : After the first valve intervention, the patient receives another valve surgical or interventional procedure due to valvular-related causes.

    2、Cardiovascular adverse events : Any new-onset or recurrent cardiovascular disease, rehospitalization for cardiovascular reasons, and cardiac death, etc.

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Yongjian Wu, MD, PhD

Other Gov

Registry information

Official study title

Third National Multicenter Registered Cohort Study of Hospitalized Elderly Patients With Valvular Heart Disease Based on the China-DVD Network

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 11, 2026
Registry last updated
Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.